In addition, studies aiming at establishing dose-response relationships of (1) ATZ on CYP19A1 induction/activity, (2) curcumin on ATZ detoxification with ATZ plasma level as the outcome measure, and (3) curcumin on counteracting ATZ’s promoting effect on breast cancer development with breast tissue proliferation index as the endpoint would be extremely valuable in supporting curcumin as a mechanism-based antidote for ATZ exposure. This evidence concerns the gene CYP19A1 and breast cancer.